These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 5818756)

  • 1. [Distribution of dipyridamole, a selective coronary dilating substance, between plasma, cellular and aqueous phase in man and dogs. A contribution on the dosage of the drug in man].
    Kübler W; Bretschneider HJ; Spieckermann PG
    Arzneimittelforschung; 1969 Feb; 19(2):185-90. PubMed ID: 5818756
    [No Abstract]   [Full Text] [Related]  

  • 2. [Action of dipyridamole (Persantin) administered per os on coronary circulation in unanesthetized dogs].
    Laubie M
    Therapie; 1971; 26(1):197-209. PubMed ID: 5554764
    [No Abstract]   [Full Text] [Related]  

  • 3. [Competitive inhibition of adenosine aminase as a possible cause of the coronary dilating effects of a pyrimidopyrimidine combination].
    Deuticke B; Gerlach E
    Naunyn Schmiedebergs Arch Pharmakol Exp Pathol; 1966; 255(1):107-19. PubMed ID: 4226571
    [No Abstract]   [Full Text] [Related]  

  • 4. [Binding of the coronary dilator dipyridamol in the plasm of man and dogs and its significance for the dosage of the drug in man].
    Kübler W; Bretschneider HJ; Spieckermann PG
    Klin Wochenschr; 1969 Jan; 47(2):108-9. PubMed ID: 5368641
    [No Abstract]   [Full Text] [Related]  

  • 5. [Plasma binding and dosis-effect interrelation of the coronary vasodilator dipyridamol in man].
    Kübler W; Rau G; Spieckermann PG; Tauchert M; Cott L; Bretschneider HJ
    Verh Dtsch Ges Inn Med; 1969; 75():413-5. PubMed ID: 5400166
    [No Abstract]   [Full Text] [Related]  

  • 6. [COMPETITIVE INHIBITION OF CATALYZED ADENOSINE DIFFUSION AS THE MECHANISM OF THE CORONARY DILATING EFFECT OF A PYRIMIDO-PYRIMIDINE DERIVATIVE].
    KUEBLER W; BRETSCHNEIDER HJ
    Pflugers Arch Gesamte Physiol Menschen Tiere; 1964 Jul; 280():141-57. PubMed ID: 14253709
    [No Abstract]   [Full Text] [Related]  

  • 7. Difference in site and time course of coronary dilating effects of trapidil, nitroglycerin and dipyridamole in anesthetized dogs.
    Noguchi K; Tomoike H; Ootsubo H; Sakai K; Nakamura M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):809-14. PubMed ID: 6795344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical aspects of persantin, segontin and trimanyl in the light of the results of experimental studies on the coronary circulation in dogs].
    Janicki K; Wcislo W
    Pol Tyg Lek; 1967 May; 22(21):779-81. PubMed ID: 6040998
    [No Abstract]   [Full Text] [Related]  

  • 9. Persantin.
    Med Lett Drugs Ther; 1966 Apr; 8(7):27-8. PubMed ID: 4956154
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of intracoronary injections of sodium tanshinone II-A sulfonate and dipyridamole on myocardial infarct size in acute ischemic dogs (author's transl)].
    Hu GJ; Zhang JG; Jiang WD; Wei PJ
    Zhongguo Yao Li Xue Bao; 1981 Mar; 2(1):34-5. PubMed ID: 6461197
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacologically-induced development of coronary collaterals in relation to dosage].
    Meesmann W; Bachmann GW
    Arzneimittelforschung; 1966 Apr; 16(4):501-9. PubMed ID: 6014261
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance.
    Strauer BE; Heidland UE; Heintzen MP; Schwartzkopff B
    J Am Coll Cardiol; 1996 Nov; 28(5):1119-26. PubMed ID: 8890804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and the heart ultrastructure with special reference to the protective action of the coronary drug Persantin.
    Lozada BB; Laguens RP
    Cardiologia (Basel); 1966; 49():Suppl 1:33-43. PubMed ID: 5989065
    [No Abstract]   [Full Text] [Related]  

  • 14. Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
    Serebruany V; Sabaeva E; Booze C; Atar OD; Eisert C; Hanley D;
    Thromb Haemost; 2009 Sep; 102(3):538-43. PubMed ID: 19718475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of coronarotropic drugs using dipyridamole as an example.
    Kadatz R
    Brux Med; 1970 Sep; 50(9):609-16. PubMed ID: 5510361
    [No Abstract]   [Full Text] [Related]  

  • 16. [Action of Persantin on the coronary circulation].
    Brugger A; Lluch S; Marco V; Esplugues J
    Rev Clin Esp; 1965 Sep; 98(6):401-4. PubMed ID: 5865268
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty (PTCA) by intracoronary dipyridamole: hemodynamic, contractile and dynamic ventricular consequences].
    Strauer BE; Heidland UE; Heintzen MP; Schwartzkopff B
    Z Kardiol; 1995 Nov; 84(11):898-910. PubMed ID: 8571641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oxygen pressure and oxygen consumption in coronary venous blood as well as the changes of the arterio-coronary venous O2 content difference and the coronary circulation with high doses of 2,6-(diethanolamino)-4,-8-dipiperidinopyrimido -(5,4-d) pyrimidine (Persantin)].
    Doll E; Keul J; Brechtel
    Z Kreislaufforsch; 1966 Nov; 55(10):1076-97. PubMed ID: 5998956
    [No Abstract]   [Full Text] [Related]  

  • 19. [On the therapy of chronic coronary insufficiency].
    Steim H; Heilmeyer L
    Med Klin; 1966 Aug; 61(31):1223-8. PubMed ID: 5988938
    [No Abstract]   [Full Text] [Related]  

  • 20. [Ultrastructural study of the myocardium of rats treated with dipyridamole and subjected to swimming exercises].
    Jiménez-Castellanos MR; Moreno J; López-Campos JL
    Rev Clin Esp; 1984 Sep; 174(6):237-41. PubMed ID: 6522705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.